I Frank Ciernik1,2, Yann Gager3, Christof Renner4, Sybille Spieker5, Nicole Arndt6, Karsten Neumann7. 1. Department of Radiotherapy and Radiation Oncology, City Hospital, Dessau, Germany. 2. University of Zürich (MeF), Zürich, Switzerland. 3. PathoNext GmbH, Leipzig, Germany. 4. Department of Neurosurgery, City Hospital, Dessau, Germany. 5. Department of Neurology, City Hospital, Dessau, Germany. 6. General Pathology, Department of Pathology, City Hospital, Dessau, Germany. 7. Molecular Pathology, Department of Pathology, City Hospital, Dessau, Germany.
Abstract
BACKGROUND: Salvage radiation therapy (SRT) can be offered to patients with relapsing glioblastoma multiforme (GBM). Here we report our experience with a schedule extending the treatment time of SRT with the aim to prolong the cytotoxic effect of ionizing radiation while minimizing the cytotoxic hazards for the surrounding brain. METHODS AND PATIENTS: From 2009 until 2017, 124 of 218 patients received radical resection, adjuvant chemo-radiation with photons and temozolomide (TMZ) followed by adjuvant TMZ. Re-irradiation was performed in 26 patients due to local relapse. Treatment schedules varied. Survival and molecular markers were assessed. RESULTS: The median survival was respectively 12 months (9-14.5) of the 124 patients treated with tri-modal therapy and 19.2 months (14.9-24.6) for the 26 patients retreated with SRT (p=0.038). Patients who received daily fractions of 1,6 to 1,65 Gy to a total dose of >40 Gy had a median survival time of 24,6 months compared to patients treated with higher daily doses or a total dose of <40 Gy (p= 0.039), consistent with the observation that patients treated with 21-28 fractions had a median survival of 21,9 months compared to 15,8 months of patients who received 5-20 fractions (p=.0.05). Patients with Ki-67 expression of >30% seemed to perform better than patients with expression levels of ≤20% (p=0.03). MGMT methylation status, TERT promoter or ATRX mutations, overexpression of p53, p16, PD-L1, and EGFR were not prognostic. CONCLUSIONS: Re-irradiation of relapsing GBM is a highly valid treatment option. Our observation challenges hypofractionated stereotactic radiotherapy for retreatment and controlled trials on the fractionation dose for SRT are needed. Robust predictive molecular markers could be beneficial in the selection of patients for SRT.
BACKGROUND: Salvage radiation therapy (SRT) can be offered to patients with relapsing glioblastoma multiforme (GBM). Here we report our experience with a schedule extending the treatment time of SRT with the aim to prolong the cytotoxic effect of ionizing radiation while minimizing the cytotoxic hazards for the surrounding brain. METHODS AND PATIENTS: From 2009 until 2017, 124 of 218 patients received radical resection, adjuvant chemo-radiation with photons and temozolomide (TMZ) followed by adjuvant TMZ. Re-irradiation was performed in 26 patients due to local relapse. Treatment schedules varied. Survival and molecular markers were assessed. RESULTS: The median survival was respectively 12 months (9-14.5) of the 124 patients treated with tri-modal therapy and 19.2 months (14.9-24.6) for the 26 patients retreated with SRT (p=0.038). Patients who received daily fractions of 1,6 to 1,65 Gy to a total dose of >40 Gy had a median survival time of 24,6 months compared to patients treated with higher daily doses or a total dose of <40 Gy (p= 0.039), consistent with the observation that patients treated with 21-28 fractions had a median survival of 21,9 months compared to 15,8 months of patients who received 5-20 fractions (p=.0.05). Patients with Ki-67 expression of >30% seemed to perform better than patients with expression levels of ≤20% (p=0.03). MGMT methylation status, TERT promoter or ATRX mutations, overexpression of p53, p16, PD-L1, and EGFR were not prognostic. CONCLUSIONS: Re-irradiation of relapsing GBM is a highly valid treatment option. Our observation challenges hypofractionated stereotactic radiotherapy for retreatment and controlled trials on the fractionation dose for SRT are needed. Robust predictive molecular markers could be beneficial in the selection of patients for SRT.
Authors: Peter Hau; Ulrike Baumgart; Katharina Pfeifer; Anne Bock; Tanya Jauch; Jörg Dietrich; Klaus Fabel; Oliver Grauer; Caecilia Wismeth; Monika Klinkhammer-Schalke; Michael Allgäuer; Gerhard Schuierer; Horst Koch; Juergen Schlaier; Winfried Ulrich; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher Journal: Cancer Date: 2003-12-15 Impact factor: 6.860
Authors: Andreas H Scheel; Gudrun Baenfer; Gustavo Baretton; Manfred Dietel; Rolf Diezko; Thomas Henkel; Lukas C Heukamp; Bharat Jasani; Korinna Jöhrens; Thomas Kirchner; Felix Lasitschka; Iver Petersen; Simone Reu; Hans-Ulrich Schildhaus; Peter Schirmacher; Kristina Schwamborn; Ulrich Sommer; Oliver Stoss; Markus Tiemann; Arne Warth; Wilko Weichert; Jürgen Wolf; Reinhard Büttner; Josef Rüschoff Journal: Histopathology Date: 2017-11-21 Impact factor: 5.087
Authors: Felix Bokstein; Deborah T Blumenthal; Benjamin W Corn; Eliahu Gez; Diana Matceyevsky; Natan Shtraus; Zvi Ram; Andrew A Kanner Journal: J Neurooncol Date: 2015-11-24 Impact factor: 4.130
Authors: Oliver Oehlke; Michael Mix; Erika Graf; Tanja Schimek-Jasch; Ursula Nestle; Irina Götz; Sabine Schneider-Fuchs; Astrid Weyerbrock; Irina Mader; Brigitta G Baumert; Susan C Short; Philipp T Meyer; Wolfgang A Weber; Anca-Ligia Grosu Journal: BMC Cancer Date: 2016-10-05 Impact factor: 4.430
Authors: Martin van den Bent; Hui K Gan; Andrew B Lassman; Priya Kumthekar; Ryan Merrell; Nicholas Butowski; Zarnie Lwin; Tom Mikkelsen; Louis B Nabors; Kyriakos P Papadopoulos; Marta Penas-Prado; John Simes; Helen Wheeler; Tobias Walbert; Andrew M Scott; Erica Gomez; Ho-Jin Lee; Lisa Roberts-Rapp; Hao Xiong; Earle Bain; Peter J Ansell; Kyle D Holen; David Maag; David A Reardon Journal: Cancer Chemother Pharmacol Date: 2017-10-26 Impact factor: 3.333
Authors: Maxim O Politko; Alexandra Y Tsidulko; Oxana A Pashkovskaya; Konstantin E Kuper; Anastasia V Suhovskih; Galina M Kazanskaya; Lyubov S Klyushova; Dmitry K Sokolov; Alexander M Volkov; Evgenii E Kliver; Alexander A Zheravin; Svetlana V Aidagulova; Elvira V Grigorieva Journal: Int J Mol Sci Date: 2021-12-12 Impact factor: 5.923